摘要 ：近日，成都中医药大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出19项仪器设备采购意 向，预算总额达2.99亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 成都中医药大学发布 19 项仪器设备采购意向，预算总额达 2.99 亿 元，涉及机载高光谱成像光谱仪、多功 能电路制作仪、柔性电子快速制板仪、多模态脑功能测试仪、空间电子三维打印机 、全电动倒置荧光显微镜 等，预计 采购时间为2025年 10 月。 部分采购仪器简介： 柔性电子快速制板仪 | （第 | | | | | --- | --- | --- | --- | | 一 | | | | | 期） | | | | | —中 | | | | | 医药 | | | | | 数智 | | | | | 化创 | | | | | 新研 | | | | | 究平 | | | | | 台智 | | | | | 教采 | | | | | 购项 | | | | | 目 | | | | | 超长 | | | | | 期国 | | | | | 债中 | | | ...

近日，山西省大同市塔山煤矿矿区，基层矿工们迎来一位"AI郎中"。 脉诊仪精准把脉，舌诊仪高清采样，问诊仪个性化交互……记者按照提示依次通过8台智能设备，不到 20分钟，一份详细的中医体检报告便已生成。 "中医传统的'望闻问切'，正借助智能检测设备得到延伸与辅助。"中国中医科学院博士刘奕清介绍，智 能检测设备采集数据后，通过自研"大医金匮"中医大模型进行分析，最终给出体检报告和调理方案。 长期在阴湿井下工作的矿工常面临关节疼痛、尘肺等健康风险。这样一份融合了传统中医智慧与智能科 技的报告，为他们提供了个性化的健康调理方案。 "报告非常详细，和我平时感受到的症状很吻合，还给出了具体的食疗、穴位按摩、运动等建议。"刚做 完体检的塔山煤矿职员孟女士打算依照建议好好调养。 中医智能检测厅。新华社记者徐鹏航 摄 塔山煤矿职工正在通过脉诊仪进行中医体检。新华社记者徐鹏航 摄 这一移动中医智能检测厅背后，是中国中医科学院长达十年的技术攻坚。 "以脉诊仪为例，最大的难点在于如何精准定位脉象。"中国中医科学院中医基础理论研究所副所长赵宇 平介绍，团队通过先进视觉算法模块，实现寸、关、尺快速准确定位。同时，通过实时压力信号反馈， ...

新华网北京9月29日电（逦琛）近期，一款名为"小儿智力糖浆"的中成药因其特殊的名字引发社会热 议。一些家长望文生义，将其理解为"提高智商的保健品"；网络舆论中也不乏质疑声音，认为这类中成 药缺乏循证证据支撑。事实上，这一药品早在上世纪八十年代就已进入临床应用，并被权威指南收录， 临床研究不断积累，相关质量标准也在逐步升级。 中：国家中医药管理局重点学科南京中医药大学中医儿科学科带头人、卫生部国家临床重点专科江苏省 中医院儿科负责人 韩新民 围绕"小儿智力糖浆"，存在着公众认知、学术研究、监管保障三方面的交汇点。它到底是一种"智商 药"，还是有循证证据支撑的处方药？在新华网的采访中，专家们从中医药经典传承、现代循证研究、 临床使用与监管保障等角度展开解读，帮助还原其真实面貌。 左：中国中药协会儿童药物研究委员会委员、 2020 年 ADHD 诊疗培训认证体系核心专家 朱萍 事实上，医学诊断有着明确标准。临床医生会结合患儿的病史、症状表现和中医辨证，判断是否属于 ADHD（注意缺陷多动障碍）或抽动症等神经发育障碍，进而决定是否用药。朱萍指出："家长凭直观 观察往往无法准确分辨，孩子'坐不住'并不等于多动症。只有经 ...

张伯礼在普及中医药知识。 人民网记者 崔新耀摄 葛 根 虎 杖 杜 仲 杨华勇讲解盾构机工作原理。 郭 扬摄 具有自主知识产权的国产盾构机。 浙江大学供图 数据来源：中国科协 山东省青岛市莱西市河头店镇中心中学学生在体验VR项 目。 张进刚摄（人民视觉） 作为首个全国科普月的特别活动，讲座之后，张伯礼院士又把课堂搬到了校园西北角的天津中药植物园 （又称"如意药岭"），带着学生开启一场别开生面的科学漫步。 随时开展可见可触的科普 江苏省泰州市姜堰区淮海小学，学生与智能机器人互动。 周社根摄（人民视觉） 新修订的《中华人民共和国科学技术普及法》规定，每年9月为全国科普月。今年首个全国科普月的主 题为"科技改变生活 创新赢得未来"，聚焦宣传推广科技创新成果、弘扬科学精神和科学家精神、广泛 开展群众性科普等内容，多地推出的科普游园、科学漫步等活动受到公众欢迎。 本期"院士讲科普"推出全国科普月特别报道，让我们跟随中国工程院院士张伯礼打卡天津中药植物园、 跟着中国工程院院士杨华勇走进浙江大学高端装备研究院，感受科技改变生活的真切脚步，感受崇尚创 新的浓厚社会氛围。 ——编 者 在天津中药植物园—— 张伯礼院士教年轻人如 ...

会上，明东首先详细介绍了天津大学的发展历史、学术成就以及科研实力并全面回顾了学校与鲁南制药集团已有的科研与人才合作基础。他指出，天津大 学始终坚持医工交叉创新驱动医药事业发展，以国家战略需求为导向，致力于医工结合、产教融合，在药学、生命科学、精密仪器等领域拥有雄厚的科研 实力和人才优势。未来，希望双方在联合技术研发、学生实践基地建设、博士后培养、学术交流等方面开展多层次、多形式的合作，共同为推动中医药现 代化和健康中国建设贡献力量。 张贵民在介绍《生命的中医药思考》时，从中医药的理论精髓出发，结合鲁南制药集团在中药现代化、标准化、国际化方面的探索与实践，深入浅出地阐 述了中医药在维护人类健康中的独特价值和未来发展方向。他强调，传承精华、守正创新对于中医药事业的发展极其重要。未来，期待双方进一步拓展在 科研攻关、成果转化和高端人才培养等方面的合作空间，携手开展更多前沿性、突破性的科研项目，培育符合产业需要的高素质复合型人才，服务于国家 战略需求和推动经济社会高质量发展。 双方代表签署了"鲁南制药-脑机海河发展基金"和"院长教育基金"，明东为张贵民颁发天津大学导师聘书。 齐鲁晚报.齐鲁壹点通讯员曹婷婷徐亲红 9月 ...

Core Viewpoint - The collaboration between Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. and JD Health marks a significant step in the internationalization of traditional Chinese medicine, enhancing the brand's global presence and recognition [1][2]. Group 1: International Expansion - Pien Tze Huang has been actively expanding its international footprint, recently participating in events like the "2025 (China) Eurasian Commodity Trade Expo" and the "Fourth China-Africa Economic and Trade Expo" to showcase Chinese medicine culture [1][2]. - The company has established a strong reputation in the overseas Chinese community and ranks among the top exporters of traditional Chinese medicine products [1]. Group 2: Product and Market Development - Pien Tze Huang is focusing on integrating traditional Chinese medicine with modern health concepts to attract the Z generation consumer group [2]. - The company is diversifying its product lines into cosmetics, daily chemicals, and health foods, aiming to combine traditional Chinese medicine culture with modern wellness and beauty trends [2]. Group 3: Research and Development - The company is enhancing its research and development capabilities, with plans to advance two new drug projects and 18 ongoing research initiatives in the first half of the year [2]. - Pien Tze Huang aims to modernize and internationalize the traditional Chinese medicine industry, leveraging innovative development strategies to upgrade its brand value [2].

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Shaanxi Panlong Pharmaceutical Group Co., Ltd. for the first half of 2025, emphasizing growth in revenue and the company's commitment to traditional Chinese medicine and innovative healthcare solutions [1][2][3]. Financial Performance - The company's operating revenue for the first half of 2025 was approximately 574 million yuan, representing a 26.06% increase compared to the same period last year [2]. - The net profit attributable to shareholders was approximately 60.14 million yuan, showing a slight increase of 0.81% year-on-year [2]. - The net cash flow from operating activities decreased by 43.66% to approximately 62.62 million yuan [2]. - Total assets increased by 3.61% to approximately 2.36 billion yuan, while net assets attributable to shareholders rose by 1.79% to approximately 1.66 billion yuan [2]. Industry Context - The report discusses the growing elderly population in China, with over 31 million people aged 60 and above, highlighting the increasing demand for healthcare services and products [3]. - Traditional Chinese medicine is positioned as a core pillar of the national health strategy, with a focus on modernization and integration into the broader healthcare system [3][4]. - The company aims to leverage its strengths in traditional medicine to address chronic disease management, particularly for the aging population [4]. Strategic Initiatives - The company is focused on becoming a leader in the field of traditional Chinese medicine for rheumatology and pain management, utilizing a comprehensive service network to enhance patient care [4]. - It has developed an innovative model that combines precise demand insights, flexible product supply, and digital services to improve patient engagement and market penetration [4][5]. - The company is actively participating in the formulation of industry standards and enhancing its research and development capabilities to align with national policies promoting innovation in the pharmaceutical sector [6]. Product Development - The company has increased its focus on the research and development of traditional Chinese medicine, particularly in the areas of rheumatology and chronic pain [10]. - It has established partnerships with academic institutions to foster innovation and improve product efficacy [10][11]. - The company has expanded its product offerings, including over 310 registered traditional Chinese medicine formula granules [10]. Market Position - The company's flagship product, Panlong Seven Tablets, has a market share of 7.73% in the traditional Chinese medicine sector, indicating a strong competitive position [9]. - The company has received multiple accolades for its contributions to the industry, reinforcing its brand reputation and market presence [9].

Group 1 - The core objective of the visit to Tianjin is to promote high-quality projects, talent, and funding to benefit Huimin County, thereby enhancing its high-quality development through industrial empowerment [1] - Huimin County's Secretary Wang Wei visited Huimi Valley Traditional Chinese Medicine Technology Co., Ltd., where he learned about the company's AI medical equipment in the field of traditional Chinese medicine, and expressed high recognition for its innovative practices in modernizing traditional Chinese medicine [3] - The company has obtained 18 medical device registration certificates, over 300 intellectual property rights, and has undertaken more than 10 national projects and 20 provincial projects [3] Group 2 - Wang Wei emphasized the importance of creating a comfortable environment for enterprises and entrepreneurs, and the county is committed to optimizing government services and strengthening resource guarantees [6] - The county invites enterprises to visit Huimin to explore opportunities for advanced technologies and quality projects, aiming to foster the growth of the traditional Chinese medicine industry in the region [6]

Core Viewpoint - The article emphasizes the need to modernize and industrialize traditional Chinese medicine (TCM) to revitalize its role in the new era [1] Group 1: TCM Modernization and Industrialization - The Secretary of the Shandong Provincial Committee, Lin Wu, visited the Lunan Pharmaceutical Group to promote the integration of traditional formulas with modern TCM innovations [1] - Lin Wu highlighted the importance of deepening the integration of production, education, and research to enhance TCM modernization and industrialization [1] - The focus is on leveraging comparative advantages to strengthen and optimize characteristic industries, thereby developing new productive forces tailored to local conditions [1] Group 2: Cultural Heritage and Promotion - Lin Wu also visited the Yinque Mountain Han Tomb Bamboo Slip Museum, emphasizing the need to enhance the protection and utilization of cultural relics [1] - He called for innovative exhibition methods and increased promotion to effectively tell the stories of cultural relics and their preservation [1] - The aim is to actively promote cultural "two creations" to invigorate the vitality of excellent traditional Chinese culture [1]

Group 1 - The core theme of the event was the strategic layout of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in the health industry, as presented by Chairman Qiu Huaiwei [2] - The "Heart Protection" project initiated by Tianshili Medical Group aims to address the increasing incidence of cardiovascular diseases in China, with a focus on early intervention [3][8] - Tianshili's two core products received awards at the "2025 Healthy China Brand List," highlighting their innovative approach in modern traditional Chinese medicine [6] Group 2 - Tianshili's "Heart Protection" project features a three-dimensional protective system, including the "River Protection Line," "City Smoke Line," and "Metabolic Vitality Line," to promote cardiovascular health [8] - The collaboration among Tianshili, China Resources Sanjiu, and Kunming Pharmaceutical Group showcases a differentiated strategic layout, targeting consumer health, prescription drug innovation, and the elderly health market [10] - Tianshili emphasizes academic innovation as a foundation for extending cardiovascular disease prevention from treatment to prevention, providing replicable and warm solutions for chronic disease management in China [17]